Shivraj Sangappa Shivpuje , Durgacharan A. Bhagwat , Pankaj Ashok Jadhav , Kimaya P. Joshi , Suraj N. Mali
{"title":"经皮给药抗菌肽在耐甲氧西林金黄色葡萄球菌治疗中的应用","authors":"Shivraj Sangappa Shivpuje , Durgacharan A. Bhagwat , Pankaj Ashok Jadhav , Kimaya P. Joshi , Suraj N. Mali","doi":"10.1016/j.coph.2025.102548","DOIUrl":null,"url":null,"abstract":"<div><div>Bacterial antimicrobial resistance (AMR) is of major public concern around the globe that arises when bacteria which earlier responded to the antibiotic therapy no longer respond to the same therapy and become resistant. The AMR has emerged due to the antibiotic abuse resulting in the development of multidrug-resistant (MDR) bacteria including methicillin-resistant <em>Staphylococcus aureus</em> (MRSA). The conventional antibiotics including vancomycin have nowadays become ineffective due to the gradual evolution and adaptation of bacteria to the surrounding environment. Antimicrobial peptides (AMPs) have emerged as an effective therapeutic option for the treatment of MRSA-induced skin and soft tissue infections (SSTIs). They offer broad-spectrum antibacterial activity with lower probability of drug resistance development. However, these AMPs face limitations such as proteolytic degradation, poor bioavailability, and potential cytotoxicity limiting their efficacy in clinical settings. Transdermal drug delivery platforms, including microneedles (MNs) coupled with the nano-formulations, have been developed to improve the AMP stability, bioavailability, and targeted release to avoid off-target cytotoxicity. Innovative strategies including Janus-type antibacterial dressings, bioresponsive MNs, and metal–organic frameworks (MOFs)-based nanocarriers have shown favorable results against the MRSA-induced skin infection. Numerous naturally occurring and synthetic antibacterial biopeptides and a Food and Drug Administration–approved glycopeptide, vancomycin, exhibited improved biofilm penetration and therapeutic efficacy when combined with smart MNs and nanosystems. Despite these improvements, challenges associated with AMP stability, cytotoxicity, and manufacturing costs still remain that limit its clinical translation. This review discussed the various MN-assisted deliveries of AMPs and associated challenges for the treatment of MRSA infections.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"83 ","pages":"Article 102548"},"PeriodicalIF":4.2000,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Transdermal delivery of antibacterial peptides in the management of methicillin-resistant Staphylococcus aureus\",\"authors\":\"Shivraj Sangappa Shivpuje , Durgacharan A. Bhagwat , Pankaj Ashok Jadhav , Kimaya P. Joshi , Suraj N. Mali\",\"doi\":\"10.1016/j.coph.2025.102548\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Bacterial antimicrobial resistance (AMR) is of major public concern around the globe that arises when bacteria which earlier responded to the antibiotic therapy no longer respond to the same therapy and become resistant. The AMR has emerged due to the antibiotic abuse resulting in the development of multidrug-resistant (MDR) bacteria including methicillin-resistant <em>Staphylococcus aureus</em> (MRSA). The conventional antibiotics including vancomycin have nowadays become ineffective due to the gradual evolution and adaptation of bacteria to the surrounding environment. Antimicrobial peptides (AMPs) have emerged as an effective therapeutic option for the treatment of MRSA-induced skin and soft tissue infections (SSTIs). They offer broad-spectrum antibacterial activity with lower probability of drug resistance development. However, these AMPs face limitations such as proteolytic degradation, poor bioavailability, and potential cytotoxicity limiting their efficacy in clinical settings. Transdermal drug delivery platforms, including microneedles (MNs) coupled with the nano-formulations, have been developed to improve the AMP stability, bioavailability, and targeted release to avoid off-target cytotoxicity. Innovative strategies including Janus-type antibacterial dressings, bioresponsive MNs, and metal–organic frameworks (MOFs)-based nanocarriers have shown favorable results against the MRSA-induced skin infection. Numerous naturally occurring and synthetic antibacterial biopeptides and a Food and Drug Administration–approved glycopeptide, vancomycin, exhibited improved biofilm penetration and therapeutic efficacy when combined with smart MNs and nanosystems. Despite these improvements, challenges associated with AMP stability, cytotoxicity, and manufacturing costs still remain that limit its clinical translation. This review discussed the various MN-assisted deliveries of AMPs and associated challenges for the treatment of MRSA infections.</div></div>\",\"PeriodicalId\":50603,\"journal\":{\"name\":\"Current Opinion in Pharmacology\",\"volume\":\"83 \",\"pages\":\"Article 102548\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-06-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Opinion in Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S147148922500044X\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S147148922500044X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Transdermal delivery of antibacterial peptides in the management of methicillin-resistant Staphylococcus aureus
Bacterial antimicrobial resistance (AMR) is of major public concern around the globe that arises when bacteria which earlier responded to the antibiotic therapy no longer respond to the same therapy and become resistant. The AMR has emerged due to the antibiotic abuse resulting in the development of multidrug-resistant (MDR) bacteria including methicillin-resistant Staphylococcus aureus (MRSA). The conventional antibiotics including vancomycin have nowadays become ineffective due to the gradual evolution and adaptation of bacteria to the surrounding environment. Antimicrobial peptides (AMPs) have emerged as an effective therapeutic option for the treatment of MRSA-induced skin and soft tissue infections (SSTIs). They offer broad-spectrum antibacterial activity with lower probability of drug resistance development. However, these AMPs face limitations such as proteolytic degradation, poor bioavailability, and potential cytotoxicity limiting their efficacy in clinical settings. Transdermal drug delivery platforms, including microneedles (MNs) coupled with the nano-formulations, have been developed to improve the AMP stability, bioavailability, and targeted release to avoid off-target cytotoxicity. Innovative strategies including Janus-type antibacterial dressings, bioresponsive MNs, and metal–organic frameworks (MOFs)-based nanocarriers have shown favorable results against the MRSA-induced skin infection. Numerous naturally occurring and synthetic antibacterial biopeptides and a Food and Drug Administration–approved glycopeptide, vancomycin, exhibited improved biofilm penetration and therapeutic efficacy when combined with smart MNs and nanosystems. Despite these improvements, challenges associated with AMP stability, cytotoxicity, and manufacturing costs still remain that limit its clinical translation. This review discussed the various MN-assisted deliveries of AMPs and associated challenges for the treatment of MRSA infections.
期刊介绍:
Current Opinion in Pharmacology (COPHAR) publishes authoritative, comprehensive, and systematic reviews. COPHAR helps specialists keep up to date with a clear and readable synthesis on current advances in pharmacology and drug discovery. Expert authors annotate the most interesting papers from the expanding volume of information published today, saving valuable time and giving the reader insight on areas of importance.